在男性良性前列腺增生症患者中比较单疗法与塔达拉菲尔或坦苏洛辛:一项病例对照研究
Hayder Adnan Fawzi1, Saif Nabeel Akram2, Aya Fawzi Talib3
1Department of Pharmacy, Al-Mustafa University College, Baghdad, Iraq.
Journal of advanced pharmaceutical technology & research
|September 18, 2024
概括
塔达拉菲尔和坦苏洛辛在六个月的时间内对良性前列腺激增症 (BPH) 症状表现出类似的有效性. 塔达拉菲尔显著改善了性功能,为患有中度至严重下尿路症状的男性提供了替代方案.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 药理学 药理学是指药理学的学科.
背景情况:
- 良性前列腺增生 (BPH) 是一种常见的慢性疾病,影响中年男性.
- 这种BPH会导致显著的下泌尿道症状 (LUTS).
研究的目的:
- 为了比较tadalafil和tamsulosin在治疗中度至重度BPH中的疗效.
- 评估这些治疗对泌尿学参数和性功能的影响.
主要方法:
- 一个回顾性病例控制研究,涉及100名男性BPH患者.
- 患者被分为两组:坦苏洛辛 (0.4毫克/天) 和塔达拉菲尔 (5毫克/天).
- 泌尿学参数在基线,3个月和6个月被评估.
主要成果:
- 在国际前列腺症状评分 (IPSS) 中,塔达拉菲尔和坦苏洛辛之间没有显著差异 (P = 0.448).
- 与坦苏洛辛相比,塔达拉菲尔在性交频率上显著改善 (P < 0.001).
- 前列腺特异性抗原,消除后的残留和前列腺体积在两组之间没有显著差异.
结论:
- 塔达拉菲尔 (每天5毫克) 在治疗BPH症状方面表现出与坦苏洛辛相当的疗效.
- 塔达拉菲尔在改善LUTS的同时,在勃起功能方面提供了显著的好处.
- 塔达拉菲尔是与BPH相关的中度至重度LUTS的可行的6个月治疗选择.
相关概念视频
01:20Disorders of the Male Reproductive System
354
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
354
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
134
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
134